ArticleNanomedicine (London, England)2025
Anticancer efficacy of dual-loaded SLNs with Doxorubicin (DOX) and Pterostilbene (PTS): formulation, characterization, and evaluation for breast cancer.
Article in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Molecular pathways and emerging therapeutic strategies in advanced thyroid cancer: from targeted therapy to precision oncology.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Strategies for Targeting Mitochondria in the Treatment of Breast Cancer.ACS pharmacology & translational science · 2026Review
- Nanotechnology-Driven Treatment Strategies for Breast Cancer: Recent Advances and Innovations.Oncology research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThis study aimed to develop optimized doxorubicin (DOX) and pterostilbene (PTS) co-loaded solid lipid nanoparticles (SLNs) for synergistic triple-negative breast cancer (TNBC) therapy, enhancing drug stability, tumor targeting, and therapeutic efficacy. MATERIALS &
methodsCalibration curves for DOX and PTS were validated. Synergy was assessed in MDA-MB-231 cells via Combination Index (CI) and Loewe-HSA models. SLNs were optimized using Box-Behnken Design (BBD), evaluating lipid content, surfactant concentration, and sonication time. Formulations were characterized by Zetasizer, high-resolution transmission electron microscopy (HR-TEM), Fourier-transform infrared (FTIR), X-ray powder diffraction (XRD), and differential scanning calorimetry (DSC). In in-vitro cytotoxicity, Reactive Oxygen Species (ROS) generation, apoptosis, and mitochondrial depolarization were assessed. Pharmacokinetics and tumor regression were studied in rats.
resultsThe optimal 1:4 (DOX:PTS) ratio showed strong synergy (CI = 0.83). BBD-optimized SLNs had 97.92 nm size, high entrapment (DOX: 54.%; PTS: 77.5%), and pH-responsive release (78.78% DOX at pH 5.5). SLNs exhibited enhanced cytotoxicity (IC₅₀ = 0.833 µg/mL), elevated ROS (59.5%), and apoptosis induction. In in-vivo, SLNs prolonged circulation, increased tumor accumulation, and reduced tumor volume (701.50 ± 11.83 mm
conclusionsDOX-PTS SLNs demonstrated synergistic anticancer effects, improved stability, and targeted delivery, offering a promising strategy for TNBC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.